Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
1,202.00
-2.20 (-0.18%)
Nov 18, 2026, 3:28 PM IST
Zydus Lifesciences Revenue
Zydus Lifesciences had revenue of 79.10B INR in the quarter ending September 30, 2026, with 29.17% growth. This brings the company's total for the last twelve months to 303.78B, up 24.02% year-over-year. In the fiscal year ending March 31, 2026, Zydus Lifesciences had annual revenue of 271.48B with 16.81% growth. That makes Zydus Lifesciences the 3,641st largest company in the world by revenue and 105th in India.
Revenue (ttm)
303.78B
Revenue Growth
+24.02%
P/S Ratio
3.95
Revenue / Employee
10.13M
Employees
29,980
Market Cap
1.20T
Revenue by Segment
Fiscal year ended Mar 31, 2026 See the full Zydus Lifesciences breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 271.48B | 39.07B | 16.81% |
| Mar 31, 2025 | 232.42B | 36.94B | 18.90% |
| Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
| Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
| Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 369.13B |
| Cipla | 279.89B |
| Glenmark Pharmaceuticals | 159.97B |
| Alkem Laboratories | 156.32B |
| Mankind Pharma | 153.79B |
| Divi's Laboratories | 121.91B |
| Ipca Laboratories | 104.80B |
| Emcure Pharmaceuticals | 102.34B |
Zydus Lifesciences News
- 14 days ago - Zydus Lifesciences Q2 net profit drops 27% despite 29% revenue growth - The Times of India
- 14 days ago - Zydus Lifesciences Transcript: Q2 26/27 - Transcripts
- 14 days ago - Zydus Lifesciences Quarterly report: Q2 2027 - Filings
- 14 days ago - Zydus Lifesciences Slides: Q2 2027 - Filings
- 14 days ago - India's Zydus Lifesciences posts lower profit as expenses outpace revenue growth - Reuters
- 5 weeks ago - USFDA accepts biosimilar application of Zydus and German firm for Keytruda - The Times of India
- 5 weeks ago - FDA Accepts BLA For Formycon And Zydus' Keytruda Biosimilar FYB206 ;Shares Rise - Nasdaq
- 1 month ago - Zydus Lifesciences proposes ₹1,000cr university near Ahmedabad - The Times of India